• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis.

作者信息

De Luca Giacomo, Tomelleri Alessandro, Dagna Lorenzo, Matucci-Cerinic Marco

机构信息

Unit of Immunology, Rheumatology, Allergy and Rare diseases (UnIRAR), IRCCS San Raffaele Hospital, 20132, Milan, Italy.

Vita-Salute San Raffaele University, 20132, Milan, Italy.

出版信息

Clin Rheumatol. 2021 Jul;40(7):2529-2533. doi: 10.1007/s10067-021-05733-4. Epub 2021 May 22.

DOI:10.1007/s10067-021-05733-4
PMID:34021841
Abstract
摘要

相似文献

1
The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis.系统性硬化症中B细胞的靶点：消除炎症并预防疾病早期进展为纤维化的“仲夏夜之梦”。
Clin Rheumatol. 2021 Jul;40(7):2529-2533. doi: 10.1007/s10067-021-05733-4. Epub 2021 May 22.
2
B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.在系统性硬化症的紧皮小鼠模型中，B淋巴细胞耗竭可减轻皮肤纤维化和自身免疫反应。
Am J Pathol. 2006 Sep;169(3):954-66. doi: 10.2353/ajpath.2006.060205.
3
B cells in systemic sclerosis: from pathophysiology to treatment.系统性硬化症中的 B 细胞：从病理生理学到治疗。
Clin Rheumatol. 2021 Jul;40(7):2621-2631. doi: 10.1007/s10067-021-05665-z. Epub 2021 Mar 21.
4
Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.疾病机制：免疫细胞在系统性硬化症发病机制中的作用
Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85. doi: 10.1038/ncprheum0346.
5
Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.硬皮病病理生理学最新进展：特别关注免疫炎症事件
Ann Med. 2007;39(1):42-53. doi: 10.1080/07853890601098152.
6
The immunopathogenesis of fibrosis in systemic sclerosis.系统性硬化症中纤维化的免疫发病机制。
Clin Exp Immunol. 2019 Mar;195(3):310-321. doi: 10.1111/cei.13238. Epub 2018 Dec 10.
7
Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.阿巴西普治疗可预防实验性皮肤纤维化，并诱导已建立的炎症驱动性纤维化消退。
Ann Rheum Dis. 2016 Dec;75(12):2142-2149. doi: 10.1136/annrheumdis-2015-208213. Epub 2016 Feb 24.
8
Genetic factors and systemic sclerosis.遗传因素与系统性硬化症。
Autoimmun Rev. 2016 May;15(5):427-32. doi: 10.1016/j.autrev.2016.01.016. Epub 2016 Jan 28.
9
Systemic sclerosis sine scleroderma.无硬皮病的系统性硬化症。
Adv Clin Exp Med. 2017 Aug;26(5):875-880. doi: 10.17219/acem/64334.
10
Role of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis.炎症在系统性硬化症肺部疾病中的作用：与特发性肺纤维化的比较。
J Lab Clin Med. 1986 Mar;107(3):253-60.

引用本文的文献

1
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study.利妥昔单抗在系统性硬化症中的留存率：一项长期真实世界多中心研究。
Rheumatology (Oxford). 2025 Mar 1;64(3):1284-1291. doi: 10.1093/rheumatology/keae280.
2
Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.黄芩素通过调节 B 细胞异常缓解系统性硬化症的纤维化和炎症。
BMC Complement Med Ther. 2023 Feb 21;23(1):62. doi: 10.1186/s12906-023-03885-1.
3
New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.

本文引用的文献

1
Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression.利妥昔单抗作为补救治疗，联合霉酚酸酯背景治疗，用于常规免疫抑制治疗反应不佳的进行性系统性硬化症相关间质性肺病。
Semin Arthritis Rheum. 2020 Oct;50(5):977-987. doi: 10.1016/j.semarthrit.2020.08.004. Epub 2020 Aug 8.
2
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.托西珠单抗治疗系统性硬化症：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2020 Oct;8(10):963-974. doi: 10.1016/S2213-2600(20)30318-0. Epub 2020 Aug 28.
3
系统性硬化症治疗的新时代：近期获批的疗法
J Clin Med. 2022 Aug 8;11(15):4631. doi: 10.3390/jcm11154631.
Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
利妥昔单抗治疗系统性硬化症的安全性和有效性：系统评价和荟萃分析。
Int Immunopharmacol. 2020 Jun;83:106389. doi: 10.1016/j.intimp.2020.106389. Epub 2020 Mar 12.
4
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.尼达尼布治疗系统性硬化症相关间质性肺疾病。
N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.
5
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.在当代实践中，用利妥昔单抗治疗系统性硬化症患者的结局：一项前瞻性队列研究。
Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.
6
Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.利妥昔单抗联合霉酚酸酯治疗系统性硬化症。单中心病例系列研究。
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):142-145. Epub 2018 Sep 30.
7
Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression.硬皮病皮肤炎症细胞浸润的特征：B 细胞与皮肤评分进展。
Arthritis Res Ther. 2018 Apr 18;20(1):75. doi: 10.1186/s13075-018-1569-0.
8
Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.利妥昔单抗治疗系统性硬化症的疗效和安全性：法国回顾性研究和文献复习。
Autoimmun Rev. 2018 Jun;17(6):582-587. doi: 10.1016/j.autrev.2017.12.010. Epub 2018 Apr 7.
9
Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu.系统性硬化症患者的免疫球蛋白游离轻链：与肺部受累和炎症环境的相关性。
J Clin Pathol. 2018 Jul;71(7):620-625. doi: 10.1136/jclinpath-2017-204656. Epub 2018 Jan 31.
10
Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis.利妥昔单抗治疗早期弥漫性皮肤系统性硬化症患者的开放标签试点研究的两年随访
Acta Clin Belg. 2018 Apr;73(2):119-125. doi: 10.1080/17843286.2017.1372244. Epub 2017 Sep 11.